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Abstract 
Background: Congenital malaria, defined as the presence of asexual forms of malaria parasites in the peripheral 
blood during the first 7 days of life, remains a neglected area of research. Knowledge gaps exist about prevalence and 
management of malaria in this age group. The objective of this study was to evaluate the prevalence of congenital 
malaria and the validity of a rapid diagnostic test (RDT) for its diagnosis in rural Burundi.
Methods: A cross‑sectional study was conducted in a meso‑endemic malaria context in Burundi among 290 moth‑
ers, and their newborns (n = 303), who delivered at the maternity departments of Kirundo and Mukenke Hospitals 
during March and April 2014. Peripheral blood samples were collected from all mothers/newborns pairs in order to 
examine the presence of malaria parasites with two RDT (SD‑Bioline HRP2 and Carestart pan‑pLDH) and a blood slide. 
In addition, quantitative real‑time polymerase chain reaction (PCR) was performed from the newborn peripheral sam‑
ple. Frequencies and proportions were calculated for categorical variables. Sensitivity and specificity were calculated 
with a 95 % confidence interval (CI).
Results: None of the newborns were found positive by PCR (0/303; 95 % CI 0.0–1.3). The prevalence in newborns 
born from microscopy‑positive mothers was 0 % (0/44; 95 % CI 0.0–8.0). Two newborns were positive with SD‑Bioline 
HRP2 (0.7 %, 95 % CI 0.2–2.4) but none with Carestart pan‑pLDH or microscopy. Sensitivity of the diagnostic tests 
could not be evaluated as no congenital malaria was detected. Specificity of SD‑Bioline HRP2, Carestart pan‑pLDH 
and microscopy to detect congenital malaria was 99.3 % (95 % CI 97.6–99.8), 100.0 % (95 % CI 98.3–100.0) and 100.0 % 
(95 % CI 98.8–100.0), respectively.
Conclusion: In Burundi or the Central African region, no recent prevalence studies for congenital malaria have been 
carried out. This study found that the prevalence of congenital malaria in two hospitals in Kirundo province is zero. 
RDT showed to have an excellent specificity and, therefore, can be used to rule out congenital malaria: the risk of 
overtreatment is low. However, as no cases of congenital malaria were detected, the study was not able to draw con‑
clusions about the sensitivity of the RDT, nor about risk factors for congenital malaria. Further studies evaluating the 
sensitivity of RDT for diagnosis of congenital malaria are needed.
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Background
Congenital malaria is defined as the presence of asexual 
parasites in the cord blood or peripheral blood during 
the first week of life, due to the transmission of parasites 
through the placenta just before or during the delivery 
[1]. It remains a neglected area of research with knowl-
edge gaps concerning the prevalence, the clinical presen-
tation, the risk factors, the diagnosis or treatment [2].
The prevalence of congenital malaria in sub-Saharan 
Africa is estimated between 0 and 54 % [3, 4]: the wide 
range could be attributed to differences in the definition 
of congenital malaria, the endemicity of the region and 
the level of maternal immunity, the methods and char-
acteristics of the diagnostic tool used (microscopy or 
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polymerase chain reaction) or the type of specimen col-
lected (cord blood or peripheral blood) [2].
Because of the effectiveness of the placenta as a bar-
rier, the presence of maternal antibodies and the pro-
tective effect of foetal haemoglobin (Hb F), congenital 
malaria has long been considered as a rare event [2]. Its 
true burden however might be underestimated because 
of the non-specific clinical picture and the absence or 
the delayed presentation of symptoms. It is reported that 
it might take 3–4  weeks before congenitally-infected 
infants present symptoms [5] and only 34 % of parasitae-
mic newborns would present symptoms within 3 days [6]. 
Other reasons for underestimating the burden of congen-
ital malaria are the lack of awareness among clinicians, 
overall underreporting or the lack of adequate diagnostic 
tools. PCR is more sensitive than a blood smear for the 
detection of congenital malaria, however it is not clear 
whether a positive PCR-result indicates active infection 
[7].
Neonates usually present with a low to very low para-
sitaemia: a study carried-out in four meso- and hyper-
endemic regions in Nigeria found a mean parasite density 
of 48 parasites/µL (range: 8–200), with 62 % of the neo-
nates spontaneously clearing infection within 2 days [6]. 
In Accra, Ghana newborns presented with ≤50 parasites/
µL [8] and in Burkina Faso, the mean parasite density 
among newborns was 316 parasites/µL [9].
Microscopy is the main diagnostic tool currently used 
for the diagnosis of congenital malaria but access to 
quality microscopy is often problematic in low-income 
contexts, even in hospital settings. PCR is considered as 
the most sensitive tool but is mainly used for research 
purposes. Rapid diagnostic tests (RDT) are the most 
widely used diagnostic tests for malaria; they are easy 
to use, cheap and reliable and can, therefore, be used at 
peripheral levels. However evidence is lacking about the 
use and validity of RDT for the diagnosis of congenital 
malaria; to our knowledge only one study compared the 
use of PCR, microscopy and RDT (HRP2/pLDH and First 
Response Combo) [8]. No cases of congenital malaria 
were detected by microscopy and RDT among 522 new-
borns, but 12  % were found positive by PCR. No study 
has reported the sensitivity, specificity or predictive val-
ues of RDT in neonates.
In Burundi, a sub-Saharan African country known to 
have a very high malaria burden [10], Médecins Sans 
Frontières (MSF) treated in 2013 3476 cases of severe 
malaria in a Ministry of Health (MSPLS) supported 
hospital in the North-Eastern province of Kirundo. The 
health centres treated over a half million cases of sim-
ple malaria using RDT for diagnostics and artemisinin-
based combination therapy (ACT) as first line-treatment. 
Country-wide 8023 cases of malaria in pregnancy were 
reported, and congenital malaria had never been diag-
nosed [10].
The main objectives of our study were to define the 
prevalence of congenital malaria among newborns in 
Kirundo Province, Burundi, and to assess the validity of 
RDT for the diagnosis of congenital malaria.
Methods
Study population
All mothers with their newborns who were born in 
Kirundo and Mukenke district hospitals between March 
and April 2014.
Study settings
Burundi is a Central African country with a population 
of approximately 10.5 million people. The Northern part 
is considered as a meso-endemic zone for malaria with 
transmission throughout the year and peaks during the 
two rainy seasons (February–May and October–Decem-
ber). Since 2013 MSF provides support to the MSPLS in 
the Province Sanitaire de Kirundo, with a main focus on 
severe malaria.
Study design
This was an observational cross-sectional study carried 
out in the maternity and paediatric services of Kirundo 
and Mukenke district hospitals in Kirundo-Province, 
Burundi.
Sample size and inclusion/exclusion criteria
The prevalence of malaria among children 6–59 months 
is estimated at 30.6  % using RDT (16.3  % Plasmodium 
falciparum; 14.3 % P. falciparum and/or mixed infections 
and 0 % non-P. falciparum) and at 23.8 % using micros-
copy (20.7  % P. falciparum; 2.4  % mixed infections and 
0.7 % non-P. falciparum) [11]. Data concerning the prev-
alence of congenital malaria in Burundi are not available. 
For the RDT-validity study, in order to detect P. falcipa-
rum with a sensitivity of 90 %, 138 PCR(+) samples were 
needed (α error 0.05, precision 5 %). Similar calculations 
applied for the specificity: a number of 138 PCR(−) sam-
ples were required.
Inclusion criteria were: 1/mothers and their newborns 
of 0–7  days, born in the maternity-department 2/chil-
dren 0–7 days old admitted in the paediatric department 
and their mothers. Excluded were children of 0–7  days 
having received anti-malaria treatment since birth.
Blood sample collection procedures
Approximately 100  µL of capillary blood was collected 
from mothers and newborns through finger-prick or 
heel-prick, within 18  h after delivery, for testing with 
RDT, thick smear/thin smear examination and PCR.
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The performance of two different types of RDT was 
evaluated: a histidine rich protein (HRP2)-based test and 
a parasite lactate dehydrogenase (pLDH)-based test. The 
HRP2-test was the SD Bioline Malaria Antigen Pf (HRP2) 
(Manufacturer: Standard Diagnostics Inc.), currently 
used in Burundi as well as in many other contexts. The 
pLDH-test evaluated was the Carestart Malaria pLDH 
(pan) (Manufacturer: Access Bio Inc.). Quantitative PCR 
(qPCR) was used as gold standard.
Thick and thin smears were prepared at the bedside 
from two small drops of blood applied on the same glass 
slide directly from the finger- or heel prick. Each thick 
smear was analysed with light microscopy during 6 min 
to determine parasitaemia. For positive thick smears, the 
corresponding thin smear was analysed to determine the 
Plasmodium species. All smears were analysed by two 
readers. In case of a discordant result, a third reader ana-
lysed the slide to obtain a final result. An expert micros-
copist reread 10 % of the samples as a quality control.
For the molecular diagnosis (qPCR), filter papers with 
dried blood samples were punched, and one circle of 
5  mm in diameter was used for DNA extraction with a 
QIAamp DNA blood extraction kit (Qiagen) following 
the manufacturer’s recommendations. Extracted DNA 
was eluted in 150 µL water and used for quantitative real 
time PCR (qPCR). Plasmodium falciparum qPCR target-
ing 18S gene was performed as described elsewhere [12]. 
The lower limit of detection using filter paper extracted 
DNA was 10 parasites/µL.
Questionnaire
Data were collected about the clinical condition and the 
outcome of the newborns, the clinical condition of the 
mothers, the history of malaria during the last trimes-
ter and the use of long-lasting insecticide-treated nets 
(LLIN) during pregnancy.
Informed consent, confidentiality and data analysis
Individual consent was obtained from the mother or in 
absence of the mother the representative of the eligible 
children. Separate information sheets and consent forms 
were used for the prevalence and the validity study and 
were piloted beforehand to ensure they were easy to under-
stand by the patients. The information sheet was read and 
explained to each eligible mother or to the representative 
of each eligible child. Informed consent was in writing, 
through signature on the consent declaration or, in case 
the study participant or legal representative was illiterate, 
through a mark. The study participant or representative was 
given a copy of the information sheet and consent form.
All participant records were given an identification 
code. Only the anonymous codes were entered in a 
dedicated Microsoft Excel (version 2010) database, thus 
participants could not be identified. Patient records and 
dedicated electronic database were only accessible to the 
principal investigator and data encoder. All encoded data 
related to the study objectives were crosschecked for vali-
dation with the questionnaires and laboratory registers. 
Data analysis were performed by using Epidata analysis 
software (version 2.2.2.182, EpiData Association). Base-
line characteristics were described using medians and 
interquartile ranges (IQRs) for continuous variables and 
counts and percentages for categorical data. Sensitivity, 
specificity, positive predictive value (PPV) and negative 
predictive value (NPV) variables were calculated with a 
95 % confidence interval.
Results
During the study period a total of 290 mothers delivered 
in Kirundo and Mukenke maternity wards of a total of 303 
newborns. All 290 mothers were willing to participate, 
thus 290 mothers and 303 newborns were included in 
the study. The characteristics of the study participants are 
summarized in Table 1. Among the mothers 25 % reported 
a malaria episode during the last trimester of pregnancy 
of which all of them had been treated. Only 26  % slept 
under a LLIN the night before admission in the hospital. 
While 44 (15  %) were tested microscopy-positive for P. 
falciparum with a mean parasitaemia of 483 parasites/µL 
(ranges: 64–490667) during their delivery, only 6 % had a 
Table 1 Demographic and clinical characteristics of moth-
ers and  newborns, Kirundo and  Mukenke hospitals, 
Burundi (March–April 2014)
IQR interquartile range, ND no data, LLIN long-lasting insecticide-treated nets
Characteristics Mothers Newborns
N = 290 (%) N = 303 (%)
Age (median; IQR) 25 years (21–30) 1 day (1–1)
Gender
 Male – 148 (50)
 Female – 150 (50)
Birthweight in grams (median; IQR) – 2900 (2200–3200)
Gravidity (median; IQR) 3 (1–5) –
Clinical signs N = 276 (%) N = 292 (%)
 Fever 15 (6) 5 (2)
 Hypothermia – 33 (11)
 Severe anaemia 6 (3) ND
Outcomes
 Malaria in pregnancy 109 (38) –
 Malaria 3rd trimester 73 (25) –
 Malaria treated (n = 73) 73 (100) –
 Possession LLIN 179 (62) –
 Slept under LN night before 
admission
76 (26) –
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fever (>38.2 °C). Among the newborns, 85 (28 %) had a low 
birthweight (<2500 g) and 2 % were observed with a fever. 
No newborns suspected with congenital malaria were 
admitted in the paediatric service during the study.
None of the newborns were found positive by PCR 
(0/303, 95  % CI 0.0–1.3) (Table  2). The prevalence in 
newborns from microscopy-positive mothers was 0  % 
(0/44, 95  % CI 0.0–8.0). Two newborns were positive 
with the SD-Bioline HRP2 (0.7 %, 95 % CI 0.2–2.4) while 
none of the newborns were found positive with the Car-
estart pan-pLDH or microscopy. Both newborns were 
asymptomatic, received treatment and were discharged. 
The RDT positive neonates were from two mothers with 
a high parasitaemia (99,520 and 454,061 parasites/µL 
respectively) and positive SD Bioline HRP2 and Carestart 
pan-pLDH results. Both mothers had no fever or other 
symptoms, but reported to have had malaria during the 
3rd trimester of pregnancy which was treated with ACT. 
Because of supply problems during the study a propor-
tion of newborns and mothers was not tested with the 
Carestart pan-pLDH RDT.
As no congenital malaria was detected with qPCR it 
was not possible to evaluate the sensitivity of the diag-
nostic tests. However, the specificity of the SD-Bioline 
HRP2, the Carestart pan-pLDH and microscopy to 
detect congenital malaria was 99.3 % (95 % CI 97.6–99.8), 
100.0 % (95 % CI 98.3–100.0) and 100.0 % (95 % CI 98.8–
100.0), respectively (Table 3). Because of the absence of 
qPCR positive newborns it was decided not to perform 
qPCR on the samples of the mothers.
Discussion
The results of this study show a zero prevalence of con-
genital malaria among newborns in two hospitals in the 
meso-endemic region of Kirundo. Due to the absence of 
qPCR-positive cases, the sensitivity of the RDT and the 
risk factors for congenital malaria could not be assessed. 
Both types of RDT and microscopy had a very high speci-
ficity and can therefore be used to rule out congenital 
malaria; the risk of giving unnecessary treatment is low.
Only one other study used RDT for the diagnosis of 
congenital malaria, in which none of the newborns was 
found RDT-positive. Nothing was reported on RDT sen-
sitivity/specificity [8].
The prevalence of congenital malaria found in our 
study may be explained by several factors. First, a zero 
prevalence seems surprising because the survey was 
carried-out during the wet, high transmission season in 
a meso-endemic malaria setting. On the other hand it 
might be assumed that mothers had acquired a higher 
level of immunity during the high transmission sea-
son and their malaria specific antibody responses were 
boosted when exposed to malaria infection. The trans-
placental passage of these maternal antibodies could 
have contributed to the clearance of congenital infections 
occurring among newborns of high-transmission set-
tings. However there seems to be no consensus about the 
effect of the level of malaria endemicity or the malaria 
season on the prevalence of congenital malaria, as some 
studies report a higher prevalence during the wet season 
[13, 14], while others suggest that newborns are more 
protected during the transmission season [4, 15].
Secondly, none of the newborns born from RDT or 
microscopy-positive mothers was found to be qPCR-
positive, not even from mothers with very high parasi-
taemia, which could confirm the role of the placenta as 
effective barrier. The fact that two newborns from moth-
ers presenting with high parasitaemia tested positive 
with the HRP-2 RDT, but both qPCR-negative, suggests 
that the HRP-2 antigen could pass the placenta, causing 
the RDT to be positive, while the deoxyribonucleic acid 
(DNA) is not transmitted. This study could not confirm 
Table 2 Results diagnostic tests in  mothers and  newborns, Kirundo and  Mukenke district hospitals, Burundi (March–
April 2014)
SD standard diagnostics, HRPII histidine rich protein, pLDH parasite lactate dehydrogenase, RT-PCR real-time polymerase chain reaction
Mothers N Positive N (%)
Rapid diagnostic test
 SD bioline HRPII 286 85 (30)
 Carestart pan‑pLDH 204 23 (11)
Microscopy 285 44 (15)
Newborns N Positive N (%)
Rapid diagnostic test
 SD bioline HRPII 294 2 (0.7)
 Carestart pan‑pLDH 210 0
Microscopy 296 0
RT‑PCR 303 0
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that newborns from mothers with high parasitaemia are 
more likely to have parasites [16].
Third, the measures to prevent malaria in pregnancy 
are poorly implemented. A nationwide survey carried-out 
in 2012 reported that only 52 % of the pregnant women 
in the Northern Region slept under a LN the night before 
the survey [11]. The use of Antenatal Care (ANC) is low: 
in 2013 the coverage of ANC3 was 60  % while 35  % of 
women had their first ANC-visit only in their third tri-
mester of pregnancy [10]. The Intermittent Preventive 
Treatment in pregnancy (IPT-p), recommended by the 
World Health Organization (WHO), was not yet imple-
mented in Burundi in 2013. A combination of high trans-
mission and low coverage of preventive measures results 
in high exposure to malaria infection and possibly a con-
siderable prevalence of congenital malaria. The reasons 
why the prevalence of congenital malaria was found so 
low in Kirundo region, despite the high transmission and 
low coverage of preventive interventions, are not fully 
understood.
Since the year 2000, studies on congenital malaria have 
been carried-out mainly in western Africa and recent 
data about the occurrence of congenital malaria in the 
Central African region are not available. The prevalence 
found in this study is similar to the low prevalence of 
1.4 % reported in Burkina Faso [9] or 2.2 % reported in 
Ghana [8], but lower than the numbers reported from 
studies in Nigeria [6, 17–20]. However comparisons 
between studies are difficult to make due to the differ-
ent methodologies being used (type of sample or type 
of diagnostic test), the different study populations being 
observed (symptomatic versus asymptomatic newborns) 
or the different contextual levels of malaria endemicity. 
Moreover, a review of the studies reporting the highest 
rates showed gaps in reporting or conduct of the labora-
tory procedures [19].
This study also had some limitations. First, it was not 
feasible to collect samples from placental and cord blood. 
Other studies reported various results depending on the 
type of sample collected, and in studies collecting both 
cord blood and peripheral blood the frequency or level of 
parasitaemia was lower in peripheral blood than in cord 
blood [2, 4, 19, 21–23]. Thus the collection of peripheral 
blood may have underestimated the prevalence of con-
genital malaria in the study population.
Secondly, mothers in Burundi leave the hospital within 
a maximum of 24 h after birth, often between 6 and 12 h, 
therefore, only one sample could be taken at birth. Sev-
eral authors recommend repeated sampling to evaluate 
the presence of congenital malaria; the prevalence was 
found lower in samples collected within a few hours after 
birth, compared to sampling on consecutive days [18, 19]. 
Others recommend not to exclude malaria until three 
negative smears have been obtained over 48 h [23, 24].
Third, no sick newborns suspected of congenital 
malaria were admitted in the paediatric ward during the 
whole study period, and thus the prevalence of congeni-
tal malaria among symptomatic newborns could not be 
evaluated.
Fourth, this study only assessed the prevalence among 
newborns born in Kirundo and Mukenke Hospitals. From 
all expected deliveries, about one out of four still take place 
at home [10] and, therefore, the study cannot account for 
the prevalence of congenital malaria among those.
Finally, the fact that the same laboratory technicians 
performed the RDT as well as the microscopy analysis 
might have introduced a certain bias.
Conclusions
This is the first study which has evaluated the preva-
lence of congenital malaria in Burundi, and no studies 
have been carried-out recently in the Central African 
region. The prevalence of congenital malaria was found 
to be zero. It was also one of the first studies evaluating 
the performance of RDT for the diagnosis of congeni-
tal malaria. As their specificity was very high, RDT can 
be used to rule out congenital malaria; the risk of giving 
unnecessary treatment is low. However further research 
is needed for evaluating the sensitivity of the RDT or the 
risk factors for congenital malaria.
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interval, SD standard diagnostics, HRPII histidine rich protein, pLDH parasite 
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Sensitivity – – –
Specificity 99.3 %
(95 % CI 97.6–99.8)
100 %
(95 % CI 98.3–100)
100 %





(95 % CI 98.7–100)
100 %
(95 % CI 98.3–100)
100 %
(95 % CI 98.8–100)
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